Phase I Open-Label Trial to Investigate the Pharmacokinetic Interaction Between Rifabutin or Rifampin and a Single Dose of TMC207 in Healthy Subjects.

Trial Profile

Phase I Open-Label Trial to Investigate the Pharmacokinetic Interaction Between Rifabutin or Rifampin and a Single Dose of TMC207 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Bedaquiline (Primary) ; Rifabutin; Rifampicin
  • Indications Mycobacterium avium complex infections; Tuberculosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 23 Oct 2017 Results published in the Antimicrobial Agents and Chemotherapy
    • 20 Apr 2017 New safety primary end points has been added to the study.
    • 17 Jan 2013 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top